134 related articles for article (PubMed ID: 37899576)
1. Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.
Sozer Karadagli S; Gursoy P
J Oncol Pharm Pract; 2024 Mar; 30(2):404-407. PubMed ID: 37899576
[TBL] [Abstract][Full Text] [Related]
2. Ribociclib-induced pulmonary infiltrates in a patient with breast cancer.
Ünsal O; Özet A
J Oncol Pharm Pract; 2023 Sep; 29(6):1537-1540. PubMed ID: 37524106
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
García-Trevijano Cabetas M; Lucena Martínez P; Jiménez Nácher I; Díaz Almirón M; Zamora Auñón P; Herrero Ambrosio A
Int J Clin Pharm; 2021 Aug; 43(4):893-899. PubMed ID: 33170404
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib-induced hepatotoxicity.
Er MM; Araz M; Hendem E; Eryılmaz MK; Artaç M
J Oncol Pharm Pract; 2023 Jul; 29(5):1275-1277. PubMed ID: 36762416
[TBL] [Abstract][Full Text] [Related]
5. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
6. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
7. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity.
Ippolito E; Greco C; Silipigni S; Dell'Aquila E; Petrianni GM; Tonini G; Fiore M; D'Angelillo RM; Ramella S
Breast; 2019 Aug; 46():70-74. PubMed ID: 31100573
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer.
Türkel A; Karaçin C; Öner İ; Şeyran E; Öksüzoğlu B
J Oncol Pharm Pract; 2023 Feb; ():10781552231156521. PubMed ID: 36760158
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
11. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
12. Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab.
Bayram D; Aktürk Esen S; Uçar G; Köş FT
J Oncol Pharm Pract; 2023 Sep; 29(6):1494-1497. PubMed ID: 37170613
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
14. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Onesti CE; Jerusalem G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):283-298. PubMed ID: 33233970
[No Abstract] [Full Text] [Related]
18. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.
Topcu A; Yasin AI; Shbair AT; Besiroglu M; Simsek M; Sucuoglu Z; Yurtsever I; Gucin Z; Seker M; Turk HM
J Oncol Pharm Pract; 2022 Jan; 28(1):242-246. PubMed ID: 34162247
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
20. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
